A price-fixing noose tightens around Mylan, which profiteered from the Epipen
by Michael Hiltzik, Los Angeles Times
Nov 01, 2017
3 minutes
Things are getting tough for Mylan, the generic drug maker that long has been one of our less creditable corporations.
Since December, the company has been in the crosshairs of more than 40 states investigating price-fixing in the generics industry. On Tuesday, they turned up the heat, with a motion to bring civil charges against Mylan's second-in-command, President and Executive Director Rajiv Malik.
Mylan was one of six generics companies originally sued by the coalition of states led by Connecticut
You’re reading a preview, subscribe to read more.
Start your free 30 days